Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-like with PHD and RING finger domains 2 (UHRF2) is a nuclear protein and E3 ubiquitin ligase involved in cell-cycle regulation, DNA methylation, histone modification, and DNA repair. It contains multiple functional domains including a PHD finger, SRA (SET and RING-associated) domain, and a RING finger domain. UHRF2 can ubiquitinate specific substrates (such as PCNP, cyclins, and p21) and plays roles in the maintenance of genomic stability, cell-cycle progression, and may contribute to tumorigenesis. It also participates in intranuclear degradation of polyglutamine aggregates and is implicated in cellular response to DNA damage.
Modulation of cell cycle checkpoint regulation; Induction of cell cycle arrest (through ubiquitination of cyclins); Alteration of DNA methylation and histone modification; Promotion or inhibition of protein degradation via the proteasome
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-like with PHD and RING finger domains 2 (UHRF2).